Press releases
- Innovent Delivers Oral Presentation on Clinical Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Advanced Non-small Cell Lung Cancer and Other Solid Tumors at the 2024 ESMO Virtual Plenary
- Innovent Receives Fast Track Designation from the U.S. FDA for IBI343 (TOPO1i anti-CLDN18.2 ADC) as Monotherapy for Advanced Pancreatic Cancer
- Innovent to Present Multiple Clinical Study Results of Mazdutide at the ADA's 84th Scientific Sessions
- Innovent Delivers Oral Presentation of Clinical Data of A Randomized Controlled Phase 1b Study Evaluating IBI310 (Anti-CTLA-4 Monoclonal Antibody) in Combination with Sintilimab as Neoadjuvant Treatment of Colon Cancer at 2024 ASCO Annual Meeting
- Innovent Delivers Oral Presentations at the 2024 ASCO Annual Meeting on Clinical Data of First-in-Class anti-CLDN18.2/CD3 Bispecific Antibody (IBI389) for the Treatment of Advanced Pancreatic Cancer and Gastric Cancer
- Innovent Announces Taletrectinib(ROS1 Inhibitor)Updated Data from Pivotal Phase 2 TRUST-I Study of are Published in the JCO and Orally Presentedat 2024 ASCO Annual Meeting
- Innovent Presents at the 2024 ASCO Annual Meeting on Clinical Data of anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Pancreatic Cancer or Biliary Tract Cancer
- Innovent Presents Phase 1 Clinical Data of First-in-class PD-1/IL-2α Bispecific Antibody Fusion Protein (IBI363) in Melanoma, Colorectal Cancer and other Solid Tumors at the 2024 ASCO Annual Meeting
- Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib(ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting
- Innovent Announces Picankibart (IBI112) Achieved Primary Endpoints in a Phase 3 Clinical Trial in Treating Moderate to Severe Plaque Psoriasis, and Plans to Submit NDA to the NMPA
More ▼
Key statistics
As of last trade Innovent Biologics Inc (6IB:MUN) traded at 4.52, -20.00% below its 52-week high of 5.65, set on Nov 10, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.52 |
---|---|
High | 4.52 |
Low | 4.52 |
Bid | 4.52 |
Offer | 4.60 |
Previous close | 4.24 |
Average volume | 0.00 |
---|---|
Shares outstanding | 1.63bn |
Free float | 1.51bn |
P/E (TTM) | -- |
Market cap | 57.44bn HKD |
EPS (TTM) | -0.7018 HKD |
Data delayed at least 15 minutes, as of Jun 14 2024 07:05 BST.
More ▼